Summary

General Anesthesia Drugs Market Growth & Trends

The global general anesthesia drugs market size is projected to reach USD 6.56 billion by 2030, and projected to grow at a CAGR of 3.68% from 2025 to 2030, according to a new report by Grand View Research, Inc. This projected growth is driven by several critical factors, including increasing surgical volumes, advancements in anesthesia technology, rising prevalence of chronic diseases, and supportive government initiatives. The World Health Organization (WHO) estimates that the volume of surgeries is increasing due to greater access to healthcare and the growing number of elective and emergency procedures. In 2022 alone, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally, highlighting the surge in surgical interventions required. This increase in surgical activity is fueling a heightened demand for general anesthesia, as it is crucial for ensuring patient safety and comfort during operations.

Government initiatives to expand healthcare access and improve infrastructure further support market growth. In many regions, including North America and Europe, healthcare reforms and funding are increasing the availability of surgical services and improving the quality of care. For instance, the U.S. Affordable Care Act and similar initiatives in other countries are expanding surgery access, contributing to the higher demand for general anesthesia drugs. Investments in healthcare infrastructure and new healthcare facilities enhance the anesthesia market.

Technological advancements in anesthesia play a significant role in market growth. Innovations such as target-controlled infusion systems, new anesthetic agents with improved safety profiles, and enhanced monitoring technologies contribute to the efficiency and effectiveness of anesthesia. For instance, developing anesthetics with faster onset and recovery times improves patient outcomes and drives demand.

General Anesthesia Drugs Market Report Highlights

• In 2024, the propofol segment dominated the market with a substantial share of 25.52% and is also expected to grow at the fastest CAGR during the forecast period. Propofol is renowned for its rapid onset and quick recovery times, which enhance patient comfort and procedural efficiency.

• The intravenous (IV) segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.9% during the forecast period.

• In 2024, the knee and hip replacements segment dominated the market, capturing a substantial revenue share. This dominance is driven by the increasing prevalence of osteoarthritis, advancements in surgical techniques, and demographic trends.

• In 2024, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05%.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Route of Administration
1.2.3. End Use
1.2.4. Application
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Outlook
2.2.2. Route of Administration
2.2.3. End Use
2.2.4. Application
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. General Anesthesia Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Volume of Surgical Procedures
3.2.1.2. Advancements In Anesthesia Technology
3.2.1.3. Regulatory Developments
3.2.2. Market restraint analysis
3.2.2.1. Regulatory and Compliance Challenges
3.2.2.2. Adverse Effects and Safety Concerns
3.3. General Anesthesia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis
4.1. Global General Anesthesia Drugs Market: Drug Dashboard
4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
4.3. Global General Anesthesia Drugs Market by Drug, Revenue
4.4. Sevoflurane
4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Propofol
4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Dexmedetomidine
4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Remifentanil
4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Desflurane
4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Midazolam
4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis
5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
5.4. Intravenous
5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Inhaled
5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis
6.1. Global General Anesthesia Drugs Market: End Use Dashboard
6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
6.4. Hospitals
6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Ambulatory Surgical Centers
6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. General Anesthesia Drugs Market: Application Estimates & Trend Analysis
7.1. Global General Anesthesia Drugs Market: Application Dashboard
7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
7.4. Heart Surgeries
7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Cancer
7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
7.6. General Surgery
7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Knee and hip replacements
7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Other
7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key company market share analysis, 2024
9.2.3. Baxter International Inc.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Drug benchmarking
9.2.3.4. Strategic initiatives
9.2.4. AstraZeneca
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Drug benchmarking
9.2.4.4. Strategic initiatives
9.2.5. AbbVie Inc.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Drug benchmarking
9.2.5.4. Strategic initiatives
9.2.6. B. Braun Melsungen AG
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Drug benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Fresenius SE & Co. KgaA
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Drug benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Pfizer
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Drug benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Hospira Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Drug benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Aspen Pharmacare Holdings Limited
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Drug benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Hikama Pharmaceuticals plc
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Drug benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Abbott Laboratories
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Drug benchmarking
9.2.12.4. Strategic initiatives